Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations

Pharmacogenetics

Volumn 9, Issue 3, 1999, Pages 317-326

  Kaneko, Akira ^a,e   Bergqvist, Yngve ^b   Taleo, George ^c   Kobayakawa, Takatoshi ^a   Ishizaki, Takashi ^d   Björkman, Anders ^e  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b DALARNA UNIVERSITY   (Sweden)

^c Malaria Section   (Vanuatu)

^d KUMAMOTO UNIVERSITY   (Japan)

^e DANDERYD HOSPITAL   (Sweden)

Author keywords

CYP2 C19; Malaria; Proguanil; Toxicity; Vanuatu

Indexed keywords

ANTIMALARIAL AGENT; CYCLOGUANIL; PROGUANIL;

ADOLESCENT; ARTICLE; CAPILLARY BLOOD; CHILD; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG METABOLISM; FEMALE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MALARIA FALCIPARUM; MALE; ORAL DRUG ADMINISTRATION; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; VANUATU;

ANTIMALARIALS; ARYL HYDROCARBON HYDROXYLASES; CHILD; CHILD, PRESCHOOL; CHLOROGUANIDE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; GENE FREQUENCY; HETEROZYGOTE; HOMOZYGOTE; HUMANS; INFANT; MALARIA; MIXED FUNCTION OXYGENASES;

PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX;

EID: 0032782389     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Barrett PJ, Emmins PD, Clarke PD, Bradley DJ. Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. BMJ 1996; 313:525-528.
2. Bergqvist Y, Funding L, Kaneko A, Krysèn B, Leek T. Improved method for the simultaneous determination of proguanil and its metabolites by high-performance liquid chromatography and solid-phase extraction of 100-μL capillary blood samples dried on sampling paper. J Chromatogr B 1998; 719:141-149.
3. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Clin Pharmacokinet 1995; 29:192-209.
4. Björkman A, Brohult J, Sirleaf V, Willcox M, Bengtsson E. Plasmodium falciparum resistance to pyrimethamine and chlorpoguanil -host or parasite dependent? Ann Trop Med Parasitol 1980; 74:245-248.
5. Brosen K, Skjelbo E, Flachs H. Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark. Br J Clin Pharmacol 1993; 36:105-108.
6. Brosen K, de Morais SMF, Meyer UA, Goldstein JA. A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmacogenetics 1995; 5:312-317.
7. Butler D, Maurice J, O'Brien C. Time to put malaria control on the global agenda. Nature 1997; 386:535-540.
8. Bzik DJ, Li W-B, Horii T, Inselburg J. Molecular cloning and sequence analysis of the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene. Proc Natl Acad Sci USA 1987; 84:8360-8364.
9. Carrington HC, Crowther AF, Davey DG, Levi AA, Rose FL. A metabolite of 'Paludrine' with high antimalarial activity. Nature 1951; 168:1080.
10. Cavalli-Sforza LL, Piazza A, Menozzi P, Mountain J. Reconstruction of human evolution: bringing together genetic, archaeological and linguistic data. Proc Natl Acad Sci USA 1988; 85:6002-6006.
11. Chang M. Dahl ML, Tybring G, Götharson E, Bertilsson L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995; 5:358-363.
12. Curd FHS, Davey DG, Rose FL. Studies on synthetic antimalarial drugs. X: some biguanide derivatives as new types of antimalarial substances with both therapeutic and causal prophylactic activity. Ann Trop Med Parasitol 1945; 39:208-216.
13. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6:193-201.
14. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994a; 269:15419-15422.
15. de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994b; 46:594-598.
16. de Morais SMF, Goldstein JA, Xie H-G, Huang S-L, Lu Y-Q, Xia H, et al. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 1995; 58:404-411.
17. Edstein MD, Shanks GD, Teja-Isavadharm P, Rieckmann KH, Webster HK. Oxidative activation of proguanil and dapsone acetylation in Thai soldiers. Br J Clin Pharmacol 1994; 37:67-70.
18. Eriksson B, Lebbad M, Björkman A. In vitro activity of proguanil, chlorproguanil and their main metabolites against Plasmodium falciparum. Trans R Soc Trop Med Hyg 1989; 83:488.
19. Ferguson RJ. de Morais SMF, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu G, et al. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 1998; 284:356-361.
20. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. Biochemistry 1994: 33:1743-1752.
21. Goldstein JA, Ishizaki T, Chiba K, de Morais SMF, Bell D, Krahn PM, Evans DAP. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997; 7:59-64.
22. Helsby NA, Ward SA, Edwards G, Howells RE, Breckenridge AM. The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. Br J Clin Pharmacol 1990; 30:593-598.
23. Helsby NA, Edwards G, Breckenridge AM, Ward SA. The multiple dose pharmacokinetics of proguanil. Br J Clin Pharmacol 1993; 35:653-656.
24. Horai Y, Nakano M, Ishizaki T, Ishikawa K, Zhou H-H, Zhou B-J, et al. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989; 46:198-207.
25. Ibeanu GC, Blaisdell J, Ghanayem BI, Beyeler C, Benhamou S, Bouchardy C, et al. An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics 1998a; 8:129-135.
26. Ibeanu GC, Goldstein JA, Meyer U, Benhamou S, Bouchardy C, Dayer P, et al. Identification of new human CYP2C19 alleles (CTP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J Pharmacol Exp Ther 1998b: 286:1490-1495.
27. Jurima M, Inaba T, Kadar D, Kalow W. Genetic polymorphism of mephenytoin p (4')-hydroxylation: difference between Orientals and Caucasians. Br J Clin Pharmacol 1985; 19:483-487.
28. Kaneko A, Kaneko O, Taleo G, Björkman A, Kobayakawa T. High frequencies of CYP2C19 mutations and poor metabolism of proguanil in Vanuatu. Lancet 1997; 349:921-922.
29. Kaneko A, Taleo G, Kalkoa M, Reeve PA, Ganczakowski M, Shirakawa C, et al. Malaria epidemiology, glucose 6-phosphate dehdyrogenase deficiency and human settlement in the Vanuatu Archipelago. Acta Trop 1998; 70:285-302.
30. Kaneko A, Bergqvist Y, Takechi M, Kalkoa M, Kaneko O, Kobayakawa T, et al. Intrinsic efficacy of proguanil against falciparum and vivax malaria independent of the metabolite cycloguanil. J Infect Dis 1999; 179:974-979.
31. Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 1996; 60:661-666.
32. Küpfer A, Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in Man. Eur J Clin Pharmacol 1984; 26:753-759.
33. Lell B, Luckner D, Ndjavé M, Scott T, Kremsner PG. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet 1998; 351:709-713.
34. Looareesuwan S, Viravan C, Webster HK, Kyle DE, Hutchinson DB, Canfield CJ. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg 1996; 54:62-66.
35. Maegraith BG, Tottey MM, Adams ARD, Andrews WHH, King JD. The absorption and excretion of paludrine in the human subject. Ann Trop Med Parasitol 1946; 40:493-506.
36. Masimirembwa C, Bertilsson L. Johansson I, Hasler JA, Ingelman-Sundberg M. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin Pharmacol Ther 1995; 57:656-661.
37. McLarty DG, Webber RH, Jaatinen M, Kihamia CH, Murru M, Kumano M, et al. Chemoprophylaxis of malaria in non-immune residents in Dar-es-Salaam, Tanzania. Lancet 1984; II:656-659.
38. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985; 38:402-408.
39. Persson I, Aklillu E, Rodrigues F, Bertilsson L, Ingelman-Sundberg M. S-mephenytoin hydrozylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics 1996: 6:521-526.
40. Radloff PD, Philips J, Nkeyi M, Hutchinson D, Kremsner PG. Atovaquone and proguanil for Plasmodium falciparum malaria. Lancet 1996; 347:1511-1514.
41. Roh HK, Dahl ML. Tybring G, Yamada H, Cha YN, Bertilsson L. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics 1996; 6:547-551.
42. Setiabudy R, Kusaka M, Chiba K, Darmansjah I, Ishizaki T. Dapsone N-acetylation, metoprolol α-hydroxylation, and S-mephenytoin 4-hydroxylation polymorphisms in an Indonesian population: a cocktail and extended phenotyping assessment trial. Clin Pharmacol Ther 1994; 56:142-153.
43. Setiabudy R, Kusaka M, Chiba K, Darmansjah I, Ishizaki T. Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4'-hydroxylation recruited from an Indonesian population. Br J Clin Pharmacol 1995; 39:297-303.
44. Uchida JY, Kasahara T, Bobogare A, Saefafia S, Kere N, Kawabata M, et al. The prevalence of falciparum malaria in the Solomon Islands investigated by a filter paper disk-PCR method. Jpn J Parasitol 1995; 44:119-127.
45. Ward SA, Watkins WM, Mberu E, Saunders JE, Koech DK, Gilles HM, et al. Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man. Br J Clin Pharmacol 1989; 27:781-787.
46. Ward SA, Helsby NA, Skjelbo E, Brosen K, Gram LF, Breckenridge AM. The activation of the biguanide antimalarial proguanil cosegregates with the mephenytoin oxidation polymorphism - a panel study. Br J Clin Pharmacol 1991; 31:689-692.
47. Watkins WM, Sixsmith DG. The activity of proguanil and its metabolites, cycloguanil and p-chlorophenylbiguanide, against Plasmodium falciparum in vitro. Ann Trop Med Parasitol 1984; 78:273-278.
48. Watkins WM, Chulay JD, Sixsmith DG, Spencer HC, Howells RE. A preliminary pharmacokinetic study of the antimalarial drugs, proguanil and chlorproguanil. J Pharm Pharmacol 1987; 39:261-265.
49. Watkins WM, Mberu EK, Nevill CG, Ward SA, Breckenridge AM, Koech DK. Variability in the metabolism of proguanil to the active metabolite cycloguanil in healthy Kenyan adults. Trans R Soc Trop Med Hyg 1990; 84:492-495.
50. Wattanagoon Y, Taylor RB, Moody RR, Ochekpe NA, Looareesuwan S, White NJ. Single dose pharmacokinetics of proguanil and its metabolites in healthy subjects. Br J Clin Pharmacol 1987; 24:775-780.
51. Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 1984; 36:773-780.
52. World Health Organization. International travel and health. Geneva: The Organisation; 1996.
53. Wrighton SA, Stevens JC, Becker GW, VandenBranden M. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation. Arch Biochem Biophys 1993; 306:240-245.
54. Xiao Z-S, Goldstein JA, Xie H-G, Blaisdell J, Wang W. Jiang C-H, et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther 1997; 281:604-609.